Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment
Status:
Completed
Trial end date:
2018-03-12
Target enrollment:
Participant gender:
Summary
Double-blind, placebo-controlled, cross-over design study examining the effects of a
norepinephrine alpha1 receptor antagonist (prazosin) on stress reactivity in a laboratory
stressor task.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Wisconsin, Madison
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)